FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
ALPHARETTA, Ga., May 03, 2017 -- Clearside Biomedical, Inc. (NASDAQ:CLSD) (“Clearside” or the “Company”), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its first quarter 2017 financial results will be released at approximately 7:00 a.m. ET on Wednesday, May 10, 2017. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a general business and strategic review.
The live webcast and a replay may be accessed by visiting the “Investor Relations” section at www.clearsidebio.com. Alternately, please call (844) 263-8310 (U.S.) or (213) 358-0959 (international) to participate in the live conference call. The conference ID number for the live call is 17122858. Please dial in approximately 10 minutes prior to the call. An archive of the webcast will be available until June 10, 2017.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and pre-clinical candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Contacts: Stephen Kilmer Investor Relations 678-430-8206 [email protected] Charles Deignan Chief Financial Officer 678-270-4005 [email protected]
